LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Aandelen Lijst・Theravance Biopharma Inc

Theravance Biopharma Inc

Gesloten

16.27 -0.61

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

16.24

Max

16.36

Belangrijke statistieken
By Trading Economics
Inkomsten	-66M -4.9M
Verkoop	-28M 18M
K/W Sectorgemiddelde	7.148 49.888
EPS	0.01
Winstmarge	-27.872
Werknemers	90
EBITDA	-26M -6.9M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+10.5% upside

Dividenden
By Dow Jones
Volgende Winsten	11 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-49M 822M
Vorige openingsprijs	16.88
Vorige sluitingsprijs	16.27

Theravance Biopharma Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 jun 2026, 19:20 UTC

Belangrijke Marktbewegers

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

7 jun 2026, 23:46 UTC

Marktinformatie

Nikkei Likely to Fall After U.S. Tech Selloff -- Market Talk

7 jun 2026, 23:36 UTC

Marktinformatie

Oil Prices Rise Amid Escalating Supply Disruption Concerns -- Market Talk

7 jun 2026, 18:00 UTC

Winsten

Inflation Readings, Oracle Earnings, the SpaceX IPO, and More to Watch This Week -- Barrons.com

6 jun 2026, 12:40 UTC

Acquisities, Fusies, Overnames

Correction to Texas Billionaires Article America's Resort -- WSJ

6 jun 2026, 08:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

6 jun 2026, 08:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

6 jun 2026, 04:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

6 jun 2026, 00:14 UTC

Acquisities, Fusies, Overnames

4 Arm Execs Sold $26 Million in Stock, but They Missed a High -- Barrons.com

5 jun 2026, 21:27 UTC

Winsten

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 jun 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

5 jun 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

5 jun 2026, 20:20 UTC

Acquisities, Fusies, Overnames

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 jun 2026, 20:19 UTC

Acquisities, Fusies, Overnames

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 jun 2026, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

5 jun 2026, 19:26 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

5 jun 2026, 19:26 UTC

Marktinformatie

Hog Futures Tumble to Close Week -- Market Talk

5 jun 2026, 19:10 UTC

Marktinformatie

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 jun 2026, 19:03 UTC

Marktinformatie

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 jun 2026, 18:59 UTC

Marktinformatie

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 jun 2026, 18:47 UTC

Marktinformatie

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 jun 2026, 18:34 UTC

Marktinformatie

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 jun 2026, 18:33 UTC

Acquisities, Fusies, Overnames

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 jun 2026, 17:50 UTC

Winsten

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 jun 2026, 17:27 UTC

Marktinformatie

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 jun 2026, 16:48 UTC

Acquisities, Fusies, Overnames

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 jun 2026, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

5 jun 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

5 jun 2026, 16:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

5 jun 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Theravance Biopharma Inc Prognose

Koersdoel

By TipRanks

10.5% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 18 USD 10.5%

Hoogste 21 USD

Laagste 15 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Theravance Biopharma Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Theravance Biopharma Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Theravance Biopharma Inc

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.